Drug Profile
AL 78843
Alternative Names: AL-78843Latest Information Update: 15 Apr 2019
Price :
$50
*
At a glance
- Originator Alcon
- Class Antiallergics; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic conjunctivitis
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
- 01 Aug 2016 No recent reports on development identified - Phase-II for Allergic conjunctivitis in USA (Ophthalmic)
- 01 Jul 2014 Alcon completes a phase II trial in Allergic conjunctivitis in USA (NCT02079649)